Now showing items 21-30 of 90
The Ripple Effects of a Restrictive Medicaid Formulary (editorial)
(American Journal of Managed Care, 2003-10)
A Computer Simulation Model of Pharmaceutical Innovation
(Pharmaceutical Economics: Papers Presented at the 6. Arne Ryde Symposium, Helsingborg, Sweden 1982, 1984)
Longer Patents for Lower Imitation Barriers: The 1984 Drug Act
In this paper we analyze its likely impacts on competition in the pharmaceutical industry, the incentives for innovation, and general consumer welfare.
Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future.
(Health Aff (Millwood), 2014-06)
In March 2010 Congress established an abbreviated Food and Drug Administration approval pathway for biosimilars-drugs that are very similar but not identical to a reference biological product and cost less. Because bringing ...
The Contribution of the United States, Europe and Japan in Discovering New Drugs: 1982-2003
(Incentives for Research, Development, and Innovation in Pharmaceuticals, 2012-08-09)
Increasing R&D incentives for neglected diseases: Lessons from the Orphan Drug Act
(International Public Goods And Transfer Of Technology Under A Globalized Intellectual Property Regime, 2005)
Distinguished economists, political scientists, and legal experts discuss the implications of the increasingly globalized protection of intellectual property rights for the ability of countries to provide their citizens ...
Generic Competition in the U.S. Pharmaceutical Industry
(International Journal of the Economics of Business, 2006-02)
Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act
IN 1984, Congress enacted a new law that greatly affected the economics of the pharmaceutical industry in the United States. It has been characterized as the most important legislation affecting competition in the pharmaceutical ...
How did the 2003 prescription drug re-importation bill pass the house?
(Economics and Politics, 2006-03-01)
We examine the major interest groups in the debate over allowing the re-importation of prescription drugs by utilizing a logit model and instrumental variables. Consistent with political support approach, the evidence suggests ...
AN ANALYSIS OF UNITED-STATES INTERNATIONAL COMPETITIVENESS IN PHARMACEUTICALS
(MANAGERIAL AND DECISION ECONOMICS, 1989)